Beam Therapeutics Inc. Equity-NMS: BEAM

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$17.61

Open :

$17.57

Today's high :

$17.7

Today's low :

$17.01

52W low :

$13.525

52W high :

$35.25

EPS(TTM): :

-4.5

Shares O/S :

101.16 M

Market cap :

1.73 B

What is the share price of Beam Therapeutics Inc. today?

Beam Therapeutics Inc. (BEAM) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Beam Therapeutics Inc.?

Yes, Indian Investors can invest in the Beam Therapeutics Inc. (BEAM) Share by opening an international trading account with Angel One.

How can I purchase Beam Therapeutics Inc. shares in India?

Purchasing Beam Therapeutics Inc. (BEAM) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Beam Therapeutics Inc. (BEAM) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Beam Therapeutics Inc.?

Yes, you can purchase fractional shares of Beam Therapeutics Inc. (BEAM) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Beam Therapeutics Inc.?

The market capitalization of Beam Therapeutics Inc. on January 1, 1970, is $0.

What documents are required to invest in Beam Therapeutics Inc. stocks?

In order to invest in Beam Therapeutics Inc. (BEAM) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).